New Risk • May 16
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (CA$3.79m market cap, or US$2.71m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding). Tillkännagivande • Jan 22
Xebra Brands Ltd. announced that it expects to receive CAD 0.15 million in funding Xebra Brands Ltd. announced a non-brokered private placement that it will issue up to 3,000,000 units of the Company at a price of CAD 0.05 per unit for the gross proceeds of up to CAD 150,000 on January 22, 2025. Each Unit will consist of one common share of the Company and one-half of one Common Share purchase warrant. Each Warrant will entitle the holder thereof to acquire one Common Share at an exercise price of CAD 0.10 per Warrant Share at any time for a period of twenty-four months following the closing of the Offering. It is expected that the closing of the Offering will be on or about January 30, 2025, or such other date or dates that company may determine. The offering is subject to the receipt of all regulatory approvals, including the approval of the Canadian Securities Exchange. Certain directors and officers of the Company are expected to participate in the Offering. New Risk • Jan 21
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (34% average weekly change). Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Market cap is less than US$10m (CA$3.21m market cap, or US$2.24m). Tillkännagivande • Jul 09
Xebra Brands Successfully Completes First Manufacturing Run for Elements Brand Ahead of Growing Demand in Mexico Xebra Brands Ltd. announced the successful completion of its first manufacturing run of its highly anticipated Elements line. This milestone represents a significant next step forward in Xebra Brands' commercialization efforts as the company prepares for initial distribution efforts in Mexico. The authorization for the importation, launch, and sale of the Elements Full Spectrum CBD Tinctures were granted to Elements Bioscience SAPI de C.V, a fully owned subsidiary of Xebra Brands Ltd, by Mexican regulatory authorities (COFEPRIS), and are expected to be sold in wellness and supplement stores, pharmacies and other retail channels which have accelerated their demand for new products. Tillkännagivande • Apr 17
Xebra Brands Ltd. Receives Second CBD Product Approval by COFEPRIS Xebra Brands Ltd. announced that it has received approval from the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) for its second CBD product authorization to be sold in Mexico. This latest approval marks another milestone for Xebra Brands and highlights the Company's commitment to providing high-quality CBD products to consumers in Mexico. Building on the success of its first product approval in Mexico, Xebra Brands has obtained authorization for the transportation, launch, and sale of an additional 250mg Tincture, expanding its product offerings to meet the growing demand for premium CBD options in the region. Similar to its previously approved Tangerine Flavor CBD Tincture, this new product reflects Xebra's dedication to innovation, quality, and compliance within the CBD industry. Xebra Brands' 250mg Tincture is formulated with the same dedication to quality and purity as its previous offerings. Crafted with premium CBD extract, each batch of tincture undergoes thorough testing by third-party laboratories to ensure potency and consistency. This commitment to quality ensures that consumers in Mexico have access to trusted and reliable CBD products. With the approval of its second product by COFEPRIS, Xebra Brands reaffirms its position as a leader in the Mexican CBD industry. The company remains dedicated to meeting the evolving needs of consumers and providing natural wellness solutions that promote stress relief, relaxation, and overall well-being. Tillkännagivande • Apr 05
Xebra Brands Ltd. Submits Third Product Submission to Cofepris, Expanding Elements Brand Cbd Lineup Xebra Brands Ltd. announced the submission of its third product application for approval to COFEPRIS (Federal Commission for Protection Against Sanitary Risk) in Mexico for domestic production. This latest submission underscores Xebra's commitment to delivering high-quality CBD products to consumers across the country in a variety of formats. The newest addition to Xebra's Elements brand is a topical lotion meticulously crafted to provide targeted relief and nourishment for the skin, infused with premium CBD extract. Designed with precision and care, this topical lotion offers consumers a luxurious skincare experience backed by the trusted Elements brand. With the submission of the Elements Topical Lotion, Xebra now covers three major product categories in the Mexico CBD market, including topicals, tinctures, and capsules. The Company intends to continue applying for new product offerings to domestically produce products and expand into additional categories to meet the evolving needs of its consumers. Once approved by COFEPRIS, the Elements Topical Lotion will be available for purchase nationwide, providing consumers with a trusted, domestically produced solution for their skincare needs. Tillkännagivande • Mar 08
Xebra Brands Ltd. announced that it has received CAD 1 million in funding On March 7, 2024, Xebra Brands Ltd. closed the transaction. All of the units sold under the offering were purchased by David Ross Macias Diaz under a strategic investment agreement. Following the closing of the offering, David Ross Macias Diaz holds 18.04% and 30.56% of the common shares of the Company on a non-diluted basis and partially diluted basis, respectively. The offering is subject to the final acceptance of the CSE. Board Change • Nov 23
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Erick Ponce was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Sep 21
Xebra Brands Ltd., Annual General Meeting, Nov 07, 2023 Xebra Brands Ltd., Annual General Meeting, Nov 07, 2023. Tillkännagivande • Feb 17
Xebra Brands Ltd. announced that it expects to receive CAD 0.6 million in funding Xebra Brands Ltd. announced a non-brokered private placement of up to 8,000,000 units at a price of CAD 0.075 per unit for gross proceeds of up to CAD 600,000 on February 15, 2023. Each unit consists of one common share and one half of one warrant. Each whole warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.10 per share at any time within 18 months after closing. All securities to be issued in the transaction will be subject to a 4 month and one day hold period. The transaction is subject to receipt of all required regulatory and CSE approvals. The transaction is expected to close on or around March 1, 2023. The company may pay finders' fees in cash or securities, or a combination of both, as permitted by the policies of the CSE. Board Change • Feb 07
Less than half of directors are independent Following Director Keith Dolo's arrival on 01 February 2023, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Antonio Grimaldo was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Feb 04
Xebra Brands Ltd. Appoints Keith Dolo to the Board of Directors Xebra Brands Ltd. announced that Mr. Keith Dolo has been appointed to Xebra's Board of Directors. Keith is a seasoned cannabis executive and was formerly the Founder and CEO Sproutly Canada one of Canada's early Licensed Producers. He is a partner with venture capital firms Greenbridge Capital and Nautilus Capital, as well the Co-Founder of Maverick Brands which is a growth agency & accelerator that invests in, supports, and scales high growth brands across many different industries including the Cannabis and beverage industries. Keith was previously a VP at Robert Half International for over a decade. Tillkännagivande • Dec 21
Xebra Brands Ltd. Announces District Court Orders Mexican FDA to Grant Cannabis Xebra Brands Ltd. announce, that further to its press release of December 8, 2022, a District Court judge has ruled in favor of Xebra Mexico. On December 8, 2022, Xebra announced that the Mexican Health Regulatory Agency, had formally notified Xebra's Mexican subsidiary, Desart MX, SA de CV, with a resolution in which it claimed to have complied with the Supreme Court mandate to grant Xebra cannabis authorizations. Xebra however indicated that in its opinion, and in the opinion of its legal advisors, the resolution issued by the COFEPRIS did not fulfill the mandate of the Supreme Court. A District Court judge has now reviewed the COFEPRIS resolution and ruled in favor of Xebra Mexico, outright rejecting its scope and language as materially insufficient and upholding Xebra's irrefutable legal rights granted by the Supreme Court. Thus, the judge ordered the COFEPRIS to issue the full and proper authorizations within 3 business days. Due to many Mexican government offices closing during the holiday season, Xebra anticipates the process of issuing the authorizations to continue into January 2023. Furthermore, since these cannabis authorizations are without legal precedent in Mexico, guidance on approximate timing cannot be relied upon, and additional delays can be reasonably expected. Xebra Mexico's authorizations will apply specifically to cannabis with low-levels of THC (under 1%), therefore, in practical terms, to hemp cultivation, processing, and to the manufacture and sale of mainly CBD products, and certain uses of the cannabis flower. Opportunities in the hemp plastics industries have also been identified. Tillkännagivande • Nov 18
Xebra Brands Ltd. Provides Update on the Issuance of its Mexican Cannabis Authorizations Xebra Brands Ltd. provides an update on the issuance of its Mexican cannabis authorizations. Xebra previously announced that it expected the issuance of cannabis authorizations to its Mexican subsidiary, Desart MX, SA de CV ("Xebra Mexico") in October. The Mexican Health Regulatory Agency (the Mexican FDA equivalent) (the "COFEPRIS"), has been officially ordered by the courts to grant the authorization. Since these are the first cannabis authorization in Mexico related to seed importation, cultivation, processing, and manufacturing; they are without legal precedent, hence the COFEPRIS has requested, and has been granted, extensions by the courts to issue the authorizations. The most recent extension expires in approximately two (2) weeks. Xebra and the COFEPRIS are working diligently with the aim of effecting the issuance of the authorizations as soon as possible. Xebra Mexico's authorizations will apply specifically to cannabis with low-levels of THC (under 1%), therefore, in practical terms, to hemp cultivation and processing, and to the manufacture and sale of mainly CBD products, and certain uses of the cannabis flower. Opportunities in the hemp plastics industries have also been identified. Board Change • Nov 17
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Antonio Grimaldo was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Aug 25
Xebra's Vicious Citrus Cannabis Infused Lemonade Now Selling Xebra Brands Ltd. announced that its Vicious Citrus brand of cannabis-infused lemonades is now officially retailing in Canada and available for purchase in the province of Ontario, with more provinces to follow in the coming days and weeks. Vicious Citrus is a non-carbonated THC infused lemonade beverage, with a tangy citrus flavour and a 5:1 THC /CBN ratio. With the maximum amount of psychoactive cannabinoids allowed in any Canadian listed beverage, Vicious Citrus combines 10mg of THC with 2mg of CBN (Cannabinol) and is one of only a few beverages in Canada containing CBN, a unique cannabinoid that is booming in interest across North America. Board Change • Aug 19
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Antonio Grimaldo was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jul 07
Xebra Brands Ltd. Launches Vicious Citrus THC/CBN Lemonade Xebra Brands Ltd. announced the successful completion of the first commercial production run of its Vicious Citrus cannabis infused lemonade. Availability is anticipated this summer in multiple provinces across Canada, including in Ontario, which has made an initial purchase order of 10,500 units for late July delivery; more than 1,100 retail cannabis store licences have been issued in Ontario, making it by far the most lucrative cannabis market in Canada. Xebra has engaged a national cannabis sales & marketing agency to introduce and support the growth of Vicious Citrus Lemonade to Canadian cannabis retailers. Xebra Launches Vicious Citrus THC/CBN Lemonade (CNW Group/Xebra Brands Ltd.) Xebra expects to launch additional Vicious Citrus cannabis infused beverages into the Canadian market later this year and into 2023. In addition, Xebra is evaluating opportunities to introduce Vicious Citrus andother Cannabis infused beverage brands into other countries. Tillkännagivande • Jun 25
Xebra Brands Ltd., Annual General Meeting, Aug 26, 2022 Xebra Brands Ltd., Annual General Meeting, Aug 26, 2022. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Apr 13
Xebra Brands Announces its Vicious Citrous Cannabis Infused Lemonad Xebra Brands Ltd. announced that its Vicious Citrous cannabis infused lemonade, has been accepted by the Ontario Cannabis Store (OCS), for listing and sale in the Province of Ontario, Canada. Vicious Citrus Lemonade combines 10mg of THC with 2mg of CBN (Cannabinol). Vicious Citrus is one of only a few beverages in Canada containing CBN, a unique cannabinoid that is booming in interest across North America. Tillkännagivande • Apr 12
Xebra Brands Ltd. announced that it has received CAD 1.8 million in funding On April 11, 2022, Xebra Brands Ltd. closed the transaction. The company has received total CAD 1,800,000 through issuance of 15,000,000 units at an issue price of CAD 0.12 per unit. The transaction is oversubscribed. An aggregate of 257,063 shares, 504,560 warrants and CAD 60,547 is paid in finder's fees. The securities issued in the Private Placement are subject to a hold period expiring on August 9, 2022. Tillkännagivande • Apr 01
Xebra Brands Ltd. Successfully Cultivates and Harvests First Cannabis Crop in the Netherlands Xebra Brands Ltd. announced that it has successfully cultivated and harvested its first cannabis crop in the Netherlands. Samples of the crop were collected by the Dutch government's Bureau of Medicinal Cannabis, March 25, 2022. The crop consisted of high THC ±22% cannabis flower, and flower with balanced THC ±6% and CBD± 8%. As 1 of only 5 companies to be selected by the Dutch government to participate in the medicinal cannabis cultivation pilot trial, Xebra is endeavoring to be awarded 1 of 2 licenses, providing government guaranteed revenues for each company of a minimum of approximately $80 million (€70.5 million), to supply all pharma-grade cannabis to be sold though pharmacies in the Netherlands. The selection process includes the submission of samples from three cannabis trial crops, evaluated for certain criteria, including consistency and technical parameters. The deadline for the first crop was March 29, 2022 which has now been satisfied. The deadline for submission of the second crop is September 19, 2022, and March 6, 2023, for the third and final crop. A detailed business plan must also be provided to Dutch authorities by November 14, 2022. The announcement of provisional award decision by the Dutch government is scheduled for April 3, 2023, with commencement of a Framework Agreement for commercial operations planned for May 1, 2023. Cultivation in the Netherlands is conducted in Xebra's indoor facility. Xebra's specific genetic varieties are characterized by high production, compact flowers of excellent quality and fine tasting terpene profiles, with a growth cycle of 12-16 weeks. Tillkännagivande • Mar 04
Xebra Brands Ltd. Readies for Launch of Its Unique and Pioneering Cannabis Infused Lemonade in Canada Xebra Brands Ltd. reported on its progress towards having its first cannabis beverage product, Vicious Citrus Lemonade available for sale in Canada. The Xebra team has been actively targeting the three major provinces of Alberta, British Columbia and Ontario with its differentiated product offering. Vicious Citrus Lemonade, combines 10mg of THC with 2mg of CBN (Cannabinol) per serving for an entourage experience that cannot be found in most cannabis products in Canada. To Xebra's knowledge, Vicious Citrus is one of only very few beverages in Canada containing CBN. CBN is a unique cannabinoid that is booming in interest across North America. Studies have shown that THC works synergistically with other cannabinoids to enhance the overall effect when consumed together. CBN is a cannabinoid that both consumers and researchers have growing excitement about for its adult use effects and potential medicinal benefits. In addition, Vicious Citrus Lemonade is believed to be the one and only cannabis product in Canada that utilizes emulsion IP that has undergone human testing. The human testing was carried-out with the approval of Health Canada. Tillkännagivande • Feb 26
Xebra Brands Ltd. announced that it expects to receive CAD 1.2 million in funding Xebra Brands Ltd. announced a non-brokered private placement of up to 10,000,000 units at an issue price of CAD 0.12 per unit for gross proceeds of up to CAD 1,200,000 on February 25, 2022. Each unit is comprised of one common share, and a half warrant. Each full warrant entitles the holder, on exercise, to purchase one share at a price of CAD 0.25, for a period of 12 months from the date of issue. The company may pay finder's fees of 7% in cash or shares. The transaction is subject to approval from Canadian Securities Exchange. Tillkännagivande • Nov 24
Xebra Brands Ltd. announced that it has received CAD 1.34 million in funding On November 23, 2021, Xebra Brands Ltd. closed the transaction. 